Danny L. Dearen - Mar 31, 2023 Form 4 Insider Report for Axonics, Inc. (AXNX)

Role
President & CFO
Signature
/s/ Danny L. Dearen
Stock symbol
AXNX
Transactions as of
Mar 31, 2023
Transactions value $
-$589,072
Form type
4
Date filed
4/4/2023, 08:24 PM
Previous filing
Feb 2, 2023
Next filing
Apr 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXNX Common Stock Options Exercise $94.1K +6.63K +27.65% $14.19* 30.6K Mar 31, 2023 Direct
transaction AXNX Common Stock Options Exercise $141K +5.47K +17.85% $25.82 36.1K Mar 31, 2023 Direct
transaction AXNX Common Stock Options Exercise $4.73K +2.9K +8.03% $1.63* 39K Mar 31, 2023 Direct
transaction AXNX Common Stock Sale -$395K -7.2K -18.46% $54.83 31.8K Mar 31, 2023 Direct F1, F2
transaction AXNX Common Stock Sale -$434K -7.8K -24.54% $55.68 24K Mar 31, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXNX Stock Options (Right to buy) Options Exercise $0 -6.63K -30.37% $0.00 15.2K Mar 31, 2023 Common Stock 6.63K $14.19 Direct F4
transaction AXNX Stock Options (Right to buy) Options Exercise $0 -5.47K -43.74% $0.00 7.03K Mar 31, 2023 Common Stock 5.47K $25.82 Direct F5
transaction AXNX Stock Options (Right to buy) Options Exercise $0 -2.9K -100% $0.00* 0 Mar 31, 2023 Common Stock 2.9K $1.63 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $54.49 to $55.4839. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $55.49 to $55.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 1, 2023, provided the reporting person remains in continuous service on each vesting date.
F5 The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 1, 2023, provided the reporting person remains in continuous service on each vesting date.
F6 The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.